CORRESP Filing
InMed Pharmaceuticals Inc.
Date: July 31, 2025 · CIK: 0001728328 · Accession: 0001213900-25-070119
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288594
Letter
INMED PHARMACEUTICALS INC. Suite 1445 – 885 West Georgia St.
Vancouver, British Columbia, Canada
V6C 3E8
VIA EDGAR
July 31, 2025
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: InMed Pharmaceuticals Inc. – Withdrawal of Acceleration
Request for Registration Statement on Form S-1 Originally Filed on July 9, 2025
and
Acceleration Request for Pre-Effective Amendment No. 1 to Registration Statement on Form S-1
Filed July 31, 2025
File No. 333-288594
Ladies and Gentlemen:
InMed Pharmaceuticals Inc. (the " Company ") hereby respectfully withdraws its request, previously submitted to the Securities and Exchange Commission (the " Commission ") on July 14, 2025 (the " Prior Acceleration Request "), for the effectiveness of the Company's Registration Statement on Form S-1 (File No. 333-288594) originally filed with the Commission on July 9, 2025 (the " Registration Statement ") be accelerated to occur at 5:00 p.m. (Eastern Time) on July 16, 2025 at 5:00 p.m., or as soon thereafter as practicable.
The Company has filed a Pre-Effective Amendment No. 1 to the Registration Statement via EDGAR on the date hereof and, pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby now requests that the effective date and time of the Registration Statement be accelerated to 5:00 p.m. (Eastern Time) on August 1, 2025, or as soon thereafter as practicable. This letter supercedes and replaces the Prior Acceleration Request in its entirety.
If you have any questions regarding this request, please contact Scott R. Saks of Norton Rose Fulbright US LLP at (212) 318-3151.
Sincerely,
INMED PHARMACEUTICALS INC.
Show Raw Text
CORRESP 1 filename1.htm INMED PHARMACEUTICALS INC. Suite 1445 – 885 West Georgia St. Vancouver, British Columbia, Canada V6C 3E8 VIA EDGAR July 31, 2025 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: InMed Pharmaceuticals Inc. – Withdrawal of Acceleration Request for Registration Statement on Form S-1 Originally Filed on July 9, 2025 and Acceleration Request for Pre-Effective Amendment No. 1 to Registration Statement on Form S-1 Filed July 31, 2025 File No. 333-288594 Ladies and Gentlemen: InMed Pharmaceuticals Inc. (the " Company ") hereby respectfully withdraws its request, previously submitted to the Securities and Exchange Commission (the " Commission ") on July 14, 2025 (the " Prior Acceleration Request "), for the effectiveness of the Company's Registration Statement on Form S-1 (File No. 333-288594) originally filed with the Commission on July 9, 2025 (the " Registration Statement ") be accelerated to occur at 5:00 p.m. (Eastern Time) on July 16, 2025 at 5:00 p.m., or as soon thereafter as practicable. The Company has filed a Pre-Effective Amendment No. 1 to the Registration Statement via EDGAR on the date hereof and, pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby now requests that the effective date and time of the Registration Statement be accelerated to 5:00 p.m. (Eastern Time) on August 1, 2025, or as soon thereafter as practicable. This letter supercedes and replaces the Prior Acceleration Request in its entirety. If you have any questions regarding this request, please contact Scott R. Saks of Norton Rose Fulbright US LLP at (212) 318-3151. Sincerely, INMED PHARMACEUTICALS INC. /s/ Eric A. Adams Eric A. Adams President and Chief Executive Officer cc: Netta Jagpal, InMed Pharmaceuticals Inc. Scott R. Saks, Norton Rose Fulbright US LLP Trevor Zeyl, Norton Rose Fulbright Canada LLP